October 21, 2008 - Aires Pharmaceuticals Inc., a drug development company focused on developing therapies for pulmonary conditions, announced the signing of an exclusive license agreement with the U.S. National Institutes of Health for the patented use of a nitric oxide prodrug to treat cardiopulmonary conditions.The technology, identified at the NIH’s National Heart, Blood and Lung Institute, shows that nitrite, which is converted by the body into nitric oxide, can be delivered as an effective treatment for pulmonary hypertension, myocardial infarction, transplantation and cerebral vasospasm. Aires Pharmaceuticals is developing Aironite™, a proprietary, inhalable formulation of nitrite, to treat pulmonary arterial hypertension (PAH). The company has Orphan Drug Status from the U.S. Food and Drug Administration and has completed its first Phase I clinical trial for this indication... Aires Pharmaceuticals' Press Release -
